For Healthcare Professionals OnlyPartner Portal
For questions about coronavirus/COVID-19 and using NIOX VERO®, please visit the NIOX VERO Coronavirus/COVID-19 FAQ.
With over 36 million FeNO tests performed worldwide,
NIOX® technology helps healthcare professionals to accurately
measure airway inflammation.1
Using FeNO technology, NIOX VERO has a reputation worldwide as the gold standard in FeNO testing.3,4 You can enquire about NIOX VERO and get in touch with our dedicated NIOX partners via our website.
Whilst airway inflammation is known to be the major underlying characteristic of asthma, there are few methods which directly measure this. Evaluating airway inflammation using sputum eosinophils or airway biopsy can be expensive, invasive, time-consuming, and is often not readily available. FeNO testing provides a fast and accurate method to support diagnosis and management of asthma.
The majority of patients with asthma have Type 2/eosinophilic driven airway inflammation.6 The associated higher levels of nitric oxide (NO) in their exhaled breath can be simply measured to support optimal management of the condition7
References: 1. Data on file. Circassia Ltd. October 2019 C-NIOX-0002. 2. Alving K et al. Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma. Pulm Ther. 2017 3(1):207-218. 3. Dweik RA et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011 184(5):602-15. 4. National Institute for Health and Clinical Excellence (NICE). Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NOBreath. NICE diagnostics guideline [DG12]. 2014. 5. Labeling Summary/Package Insert NIOX VERO® (EU). 000247-07, Nov 2017 6. Circassia White Paper. Summary of Evidence Supporting the Clinical Value of Monitoring Exhaled Nitric Oxide (FeNO) in the Management of Asthma. 2018 7. National Institute for Health and Clinical Excellence (NICE). Asthma: diagnosis, monitoring and chronic asthma management. NICE guideline [NG80]. 2017.